5 Aug 2024 CMB International Global Markets | Equity Research | Company Update ImmuneOnco (1541 HK) Achieved significant overseas licensing partnership NOT RATED Successful overseas licensing of PD-L1xVEGF bsAb and anti-CTLA4 mAb. ImmuneOnco reached an agreement with SynBioTx (a wholly - owned subsidiary of Instil Bio (TIL US)), pursuant to which Instil will inlicense the ex-China rights to ImmueOnco's proprietary PD-L1xVEGF bispecific molecule IMM2510, as well as its next-generation anti-CTLA-4 antibody (A ...